SCHEMBL2805693

SCHEMBL2805693

CCCCCCCCCCCCCC(=O)Oc1ccc2ccccc2c1

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CETP P11597 1/20 0.58
SMN1; SMN2 Q16637 4/20 0.54
NPC1 O15118 1/20 0.54
LMNA P02545 1/20 0.54
RAB9A P51151 1/20 0.54
KMT2A Q03164 4/20 0.53
MEN1 O00255 2/20 0.53
ALDH1A1 P00352 2/20 0.53
CYP1A2 P05177 1/20 0.53
CA2 P00918 3/20 0.52
PDGFRB P09619 1/20 0.51
PDGFRA P16234 1/20 0.51
MAPK1 P28482 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
HDAC1 Q13547 1/20 0.49
PPARG P37231 3/20 0.48
PPARA Q07869 3/20 0.48
HTR1A P08908 1/20 0.48
HTR1B P28222 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31323022 1.00 CETP (0.58) CETPSMN1; SMN2NPC1LMNARAB9A
SCHEMBL2024341 1.00 CETP (0.58) CETPSMN1; SMN2NPC1LMNARAB9A
SCHEMBL2028353 1.00 CETP (0.58) CETPSMN1; SMN2NPC1LMNARAB9A
SCHEMBL1825948 1.00 CETP (0.58) CETPSMN1; SMN2NPC1LMNARAB9A
SCHEMBL5357930 1.00 CETP (0.58) CETPSMN1; SMN2NPC1LMNARAB9A
SCHEMBL11324211 1.00 CETP (0.58) CETPSMN1; SMN2NPC1LMNARAB9A
SCHEMBL1826963 1.00 CETP (0.58) CETPSMN1; SMN2NPC1LMNARAB9A
SCHEMBL17702569 1.00 CETP (0.58) CETPSMN1; SMN2NPC1LMNARAB9A
SCHEMBL22166729 1.00 CETP (0.58) CETPSMN1; SMN2NPC1LMNARAB9A
SCHEMBL31275248 1.00 CETP (0.58) CETPSMN1; SMN2NPC1LMNARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-58087094-A None JP disclosed
US-20260137736-A1 PROBIOTIC LACTOBACILLUS STRAIN COMPOSITIONS AND APPLICATIONS THEREFOR INCLUDING FOR LEAKY GUT AND INFLAMMATION BIOMEDIT LLC (US) 2026-05-21 US disclosed
US-20260069734-A1 FRESHENING COMPOSITIONS COMPRISING CONTROLLED RELEASE MODULATORS ARYLESSENCE INC (US) 2026-03-12 US disclosed
US-12564613-B2 Strains having effects of preventing or treating cancers GENOME AND COMPANY (KR) 2026-03-03 US disclosed
EP-3897156-B1 MICROBACTERIUM ESTERAROMATICUM STRAIN, COMPOSITION COMPRISING THE SAME, AND USES THEREOF FUTURECO BIOSCIENCE S A (ES) 2025-07-09 EP disclosed
US-20250123158-A1 TEMPERATURE INDICATION LABELS MICROTEK LABORATORIES, INC. (US) 2025-04-17 US disclosed
US-12214004-B2 Strains having effects of preventing or treating cancers GENOME AND COMPANY (KR) 2025-02-04 US disclosed
CN-117916290-A Ultraviolet-curable resin composition, adhesive, sealant, insulation protective agent, and electronic circuit board 荒川化学工业株式会社 2024-04-19 CN disclosed
US-20230120822-A1 YEAST AND LACTIC ACID BACTERIA COMBINATION MINGZHIYUAN HANGZHOU BIOLOGICAL TECH CO LTD (CN) 2023-04-20 US disclosed
EP-4166648-A1 A YEAST AND LACTIC ACID BACTERIA COMBINATION Geng, Shengli (CN) 2023-04-19 EP disclosed
WO-1998014594-A2 ESTERASES, DNA ENCODING THEREFOR AND VECTORS AND HOST CELLS INCORPORATING SAME GENENCOR INTERNATIONAL, INC. (US) 1998-04-09 WO disclosed
WO-1997041214-A1 BIOCATALYSTS WITH AMINE ACYLASE ACTIVITY NOVARTIS AG (CH) 1997-11-06 WO disclosed
EP-0778949-A1 STABLE SUBSTITUTE TRYGLYCERIDES FOR USE IN CLINICAL CHEMISTRY ASSAY CONTROLS OR CALIBRATORS AND PROCESS FOR THEIR PREPARATION Chiron Diagnostics Corporation (US) 1997-06-18 EP disclosed
WO-1996007105-A1 STABLE SUBSTITUTE TRYGLYCERIDES FOR USE IN CLINICAL CHEMISTRY ASSAY CONTROLS OR CALIBRATORS AND PROCESS FOR THEIR PREPARATION CHIRON DIAGNOSTICS CORPORATION (US) 1996-03-07 WO disclosed
EP-0457735-B1 Biocatalytic process for the production of L-(-)-carnitine from crotonobetaine and strains of Proteeae for use in said process SIGMA TAU IND FARMACEUTI (IT) 1995-07-26 EP disclosed
US-5300430-A Hydration SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) 1994-04-05 US disclosed
EP-0457735-A1 Biocatalytic process for the production of L-(-)-carnitine from crotonobetaine and strains of Proteeae for use in said process Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) 1991-11-21 EP disclosed
US-4533929-A ANIONIC SURFACTANTS AS ANTIFOGGING AGENTS; DIETHYLHEXYL SULFOSUCCINATE FUJI PHOTO FILM CO., LTD. (JP) 1985-08-06 US disclosed
US-4471074-A Heat-sensitive recording materials FUJI PHOTO FILM CO., LTD. (JP) 1984-09-11 US disclosed
JP-S5887094-A HEAT-SENSITIVE RECORDING MATERIAL FUJI PHOTO FILM CO LTD 1983-05-24 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260137736-A1 PROBIOTIC LACTOBACILLUS STRAIN COMPOSITIONS AND APPLICATIONS THEREFOR INCLUDING FOR LEAKY GUT AND INFLAMMATION FABP2, SLC10A2, ALPI CETP 126/4885SMN1; SMN2 2930/4885NPC1 2028/4885
US-12214004-B2 Strains having effects of preventing or treating cancers LGALS3, B3GAT3, MKI67 CETP 1936/4885SMN1; SMN2 2782/4885NPC1 2956/4885
US-12564613-B2 Strains having effects of preventing or treating cancers PDCD1, TOP1, CD274 CETP 1372/4885SMN1; SMN2 1821/4885NPC1 3432/4885
US-20260069734-A1 FRESHENING COMPOSITIONS COMPRISING CONTROLLED RELEASE MODULATORS FFAR1, FFAR2, FFAR3 CETP 109/4885SMN1; SMN2 4319/4885NPC1 2145/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.